Mapatumumab - Human Genome Sciences

Drug Profile

Mapatumumab - Human Genome Sciences

Alternative Names: Death-receptor-4-monoclonal-antibody; DR4 mAB; DR4-monoclonal-antibody; HGS-1012; HGS-ETR1; TRAIL-R1 monoclonal antibody; TRAIL-receptor-1-monoclonal-antibody; TRM-1

Latest Information Update: 28 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Human Genome Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; TNF related apoptosis inducing ligand stimulants; TRAIL receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cervical cancer
  • Suspended Liver cancer
  • No development reported Colorectal cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 29 Nov 2017 Human Genome Sciences completes a phase II trial for Liver cancer (First-line therapy, Combination therapy, Late-stage disease) in USA, Germany, Poland, Puerto Rico, Romania, Russia and Ukraine (IV) (NCT01258608)
  • 10 Sep 2015 Phase-I/II development for Cervical cancer is ongoing in Netherlands
  • 10 Sep 2015 No recent reports on development identified - Phase-II for Multiple myeloma (Combination therapy) in USA, Canada, Australia and India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top